Keros Therapeutics, Inc. announced a strategic realignment on August 6, 2025, to exclusively prioritize the clinical advancement of KER-065 for neuromuscular diseases, with an initial focus on Duchenne muscular dystrophy (DMD). This decision includes discontinuing all material internal development activities related to cibotercept, following its earlier termination in pulmonary arterial hypertension.
For the second quarter of 2025, Keros reported a net loss of $30.7 million, an improvement compared to a net loss of $45.3 million in the second quarter of 2024. This decrease in net loss was largely due to revenue recognized from the Takeda Pharmaceuticals license agreement, partially offset by increased research and development efforts.
As of June 30, 2025, Keros held $690.2 million in cash and cash equivalents. The company projects that its remaining capital, after the planned return of $375 million to stockholders, will fund its operating expenses and capital expenditure requirements into the first half of 2028, providing a substantial runway for its focused pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.